Table 1.

Clinical trials evaluating Ang-(1-7) as a treatment for COVID-19.

ClinicalTrials.gov identifier	Phase	Status	Study title	Study design
NCT04401423	II	Completed	TXA127 for the treatment of severe COVID-19	A double-blind, placebo-controlled randomized trial in hospitalized patients with severe COVID-19 in the United States (n = 22) [39]
NCT04605887	II	Recruiting	Angiotensin 1-7 as a therapy in the treatment of COVID-19	A placebo-controlled, randomized trial in hospitalized COVID-19 patients with moderate lung disease (n = 120) [40]
NCT04778059	II	Recruiting	Safety and efficacy of USB002 (pharmaceutically formulated Ang-(1-7)) for respiratory distress due to COVID-19	Placebo-controlled, double-blind, parallel assignment, randomized trial in hospitalized COVID-19 patients in the United States (n = 184) [41]
NCT04375124	Not applicable	Recruiting	Treatment of angiotensin peptide (1-7) for COVID-19	Open-label, parallel assignment, nonrandomized trial in hospitalized COVID-19 patients in Turkey (n = 20) [42]
NCT04633772	I/II	Recruiting	Use of angiotensin-(1-7) in COVID-19	Placebo-controlled, double-blind, parallel assignment, randomized trial in hospitalized COVID-19 in Brazil (n = 130) [43]
NCT04332666	II/III	Not yet recruiting	Angiotensin-(1,7) treatment in COVID-19: the ATCO trial	Placebo-controlled, double-blind, parallel assignment, randomized trial in COVID-19 patients with respiratory failure requiring mechanical ventilation in Belgium (n = 60) [44]
NCT04570501	I/II	Not yet recruiting	Angiotensin (1-7) for the treatment of COVID-19 in hospitalized patients	Multicenter, randomized, double-blind, placebo-controlled study in hospitalized COVID-19 patients (n = 160) [45]